anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A nerve growth factor composition and a powder injection. The composition consists of a nerve growth factor, a stabilizer, a pH buffer, and water. The stabilizer is one of sorbierite, dextran, trehalose, raffinose and mannitol. The use of saccharides or sugar alcohols as a stabilizer instead of albumin can avoid hidden risks caused by viruses or other unknown components carried in albumins. In addition to the nerve growth factor, the composition comprises only the stabilizer and the pH buffer and does not contain any common surfactant or supporting agent, and therefore is safer and can significantly reduce the incidence of adverse reactions. The components of the composition are known and can be easily determined qualitatively and quantitatively. The stabilizer used has a high purity and has a wide range of sources, facilitating mass production in a long term and making it easy to control the costs and improve product quality. The stabilizer not only can protect mNGF, but also enables hNGF and rhNGF to have good stability during preparation, transportation and storage, thereby ensuring safe clinical administration and good quality control.
Eight subjects in up to 7 cohorts will be dosed. One or more subcutaneous injections of HTL0022562 will be administered. In each cohort, 6 subjects will receive HTL0022562 and 2 subjects will receive placebo.
First of all, Control group filled the "Nursing Professional Pride Scale". The control group have no intervention. They filled the scale again, after 2 week.
PURPOSE: To produce a sustained release composition by mixing an active component for the diagnosis, cure, pain-removal treatment, treatment or prevention of diseases with a specific polymer in dry state, suspending particles in a gel at a prescribed temperature, heating the suspension to form microballs and filtering the product after cooling. CONSTITUTION: One or more kinds of active components are mixed with a bio-reabsorbable and/or biodegradable polymer or copolymer in dry state to obtain particles. The particles are suspended in a hydrophilic gel (e.g. PVP or water) or a hydrophobic gel under stirring. The gel is heated to an extent to cause the melting of the particles to form microballs, cooled and then filtered to recover the microballs. The obtained particles are effective for releasing the effective amount of the active component over a prescribed period. The surface of the microball is homogeneous because it is free from active component crystal of non-microencapsulated state.
BACKGROUND: Extraction of mandibular third molars (M3Ms) is a routine procedure in oral and maxillofacial surgery, often associated with postoperative symptoms like pain, facial swelling, and trismus. This study aimed to introduce a standardized and automated protocol for swelling analysis following M3M surgery, presenting results regarding clinical conditions immediately and one-week after surgery.
METHODS: In a prospective study, 35 patients were enrolled (mean age: 24.4 ± 5.8 years) for removal of 54 M3Ms. Facial swelling was evaluated through 3D facial scans before surgery (T0), at three days (T1), and seven days (T2) post-surgery. The open-source software 3DSlicer facilitated automated analysis, including data anonymization, orientation, surface registration, qualitative comparisons, linear measurements, and volumetric quantification. Pairwise superimposition of facial models enabled qualitative, vectorial, and quantitative assessments, comparing initial conditions with swelling development at T1 and T2. Additionally, changes between T1 and T2 were also evaluated. Secondary outcomes encompassed clinical evaluations of pain, trismus (maximum mouth opening), and surgery time. Statistical analysis involved the paired Student t-test to assess longitudinal changes and analysis of variance to evaluate outcome variables concerning difficulty scores. Linear regression models correlated primary outcome variables with secondary study variables (α < 0.05).
RESULTS: Longitudinal analysis demonstrated significant but variable facial swelling, pain, and trismus at T1, followed by improvement at T2 (p < 0.001). Linear and volumetric differences correlated positively with surgery time (p < 0.05). A direct proportionality between linear and volume differences was observed, higher values at T1 correlated with higher values at T2 (p < 0.05).
CONCLUSIONS: An innovative digital workflow for precise quantification of postoperative facial changes was implemented, incorporating volumetric measurements that surpass linear assessments. Clinical conditions demonstrated a direct correlation with surgery time, deteriorating immediately and improving one-week after surgery.
BACKGROUND: The COVID-19 pandemic posed a challenge to hemodialysis (HD) patients. While most outpatient and elective medical services stopped during lockdown, HD patients continued to visit their dialysis centers. We aimed to assess how the initial phase of the pandemic affected patient care by comparing dialysis adequacy and other parameters of patient care before and during the first 10 months of the COVID-19 pandemic.
METHODS: In a retrospective multi-center observational study, all adult dialysis patients in five dialysis centers in Alexandria, Egypt were included. Dialysis adequacy, missed sessions, laboratory parameters and hospitalization were recorded. Data of the 10 months before and the 10 months after the pandemic were compared and predictors of adequacy were determined.
RESULTS: In the 388 HD patients included in the study, the number of missed sessions was higher during the pandemic with peaks during the first and second wave of the pandemic. The ratio of patients to nurses, phosphorus and parathormone levels were significantly higher during the pandemic, while urea reduction ratio, Kt/V, hemoglobin, calcium and albumin levels were significantly lower. In patients who reported difficult accessibility, missed HD sessions were higher during lockdown. Hospital admissions doubled during the pandemic, with COVID-19 infection being the main cause (45.5%). Number of patients per nurse and interdialytic weight gain were predictors of inadequate dialysis.
CONCLUSION: The COVID-19 pandemic and its related lockdown negatively affected multiple aspects of dialysis patient care. Continued access of optimum care in dialysis patients should be a priority in any future mass events.
PURPOSE: First research to evaluate the clinical efficacy and safety of flexible ureteral lithotripsy (FURSL) and percutaneous nephrolithotomy (PCNL) in the treatment of the upper ureteral stone is between 1.5 cm and 2.0 cm in diameter since there is no consensus with such ureteral stone yet.
METHODS: From December 2018 to October 2022, 104 patients with calculi in the upper ureter received percutaneous nephrolithotomy (PCNL)or flexible ureteroscopic lithotripsy (FURSL) in our institution. The clinical data of the patients in the two groups were retrospectively searched. Stone removal rate, operation time, blood loss, postoperative pain score, postoperative inflammatory factor, postoperative complication rates and ureteral obstruction three months after the operation were compared between the two groups.
RESULTS: A total of 104 patients were included in the study. The stone clearance rate and the secondary surgery rate were 88.89% and 7.41% in the FURSL group, the figures were 97.96% and 2.0% in the PCNL group (p = 0.067, 0.497). Regarding ureteral obstruction three months after the operation, there were 2 patients in FURSL group and 0 patients in PCNL group(p = 0.497).Compared to patients in FURSL group, patients in the PCNL group had shorter operation time(PCNL 71.81 ± 18.94 min vs. FURSL 86.80 ± 22.49 min, p = 0.0004), fewer complications(PCNL 20.37% vs. FURSL 6.12%), and lower postoperative inflammatory factor(p = 0.0004), yet they got more hemoglobin drop (PCNL 13.14 ± 9.81 g/L vs. FURSL 4.77 ± 3.55 g/L, p < 0.0001), higher postoperative pain scores(p = 0.0017) in the first three postoperative days and longer hospital stay (PCNL 4.96 ± 1.21 days vs. FURSL 3.60 ± 0.83 days).
CONCLUSION: Both FURSL and PCNL were effective methods for treating upper ureteral stones of 1.5-2.0 cm in diameter given the extremely high stone clearance rate and a very low secondary surgery rate, as long as rare ureteral obstruction in medium-long term observation. Additionally, FURSL can effectively reduce surgical bleeding, postoperative pain, and hospital stay, while PCNL can decrease operation time, the risk of infection, and complications. Therefore, doctors could select suitable surgical treatment for those patients depending on their different clinical situations based on these findings.
PROBLEM TO BE SOLVED: To obtain the tablet capable of being easily disintegrated with water and good in appearance by including chlorella and molokheiya. SOLUTION: This tablet is obtained by adding water to the mixture powder of chlorella with molokheiya, granulating the mixture, adding 5-20 pts.wt. of the mixture powder of the chlorella with the molokheiya to 80-95 pts.wt. of the obtained granules and subsequently tableting the mixture. The mixture powder of the chlorella with the molokheiya comprises 20-80 pts.wt. of the chlorella and 80-20 pts.wt. of the molokheiya. The granules prepared from the mixture powder of the chlorella with the molokheiya and the water are preferably cylindrical granules comprising 100 pts.wt. of the mixture powder and 1-50 pts.wt. of the water. The method does not require the employment of a lubricant on the tableting treatment, while lubricants are used by conventional methods.
A compound represented by the general formula I: I wherein A represents oxygen, sulfur, etc. B1 represents nitrogen, etc. B2 represents oxygen, etc. X1 and X2 each represents oxygen, sulfur, a bond, etc. Y represents a C1-8 alkylene chain Z represents oxygen or sulfur R1 represents optionally substituted aryl, etc. R2 represents C2-8 alkyl, etc. R3 represents C1-8 alkyl, C2-8 alkenyl, etc. R4 and R5 each represents hydrogen, C1-8 alkyl, etc. and R6 represents hydrogen, etc. provided that Z and R3 are bonded to the benzene ring and X2 is not bonded to the benzene ring or a salt of the compound and a PPARdelta activator containing the compound or salt as an active ingredient.
CALQUENCE as Monotherapy

For patients with MCL, CLL, or SLL, the recommended dosage of CALQUENCE is 100 mg taken orally approximately every 12 hours until disease progression or unacceptable toxicity.

CALQUENCE in Combination with Obinutuzumab

For patients with previously untreated CLL or SLL, the recommended dosage of CALQUENCE is 100 mg taken orally approximately every 12 hours until disease progression or unacceptable toxicity. Start CALQUENCE at Cycle 1 (each cycle is 28 days). Start obinutuzumab at Cycle 2 for a total of 6 cycles and refer to the obinutuzumab prescribing information for recommended dosing. Administer CALQUENCE prior to obinutuzumab when given on the same day.

Advise patients to swallow tablet whole with water. Advise patients not to chew, crush, dissolve, or cut the tablets. CALQUENCE may be taken with or without food. If a dose of CALQUENCE is missed by more than 3 hours, it should be skipped and the next dose should be taken at its regularly scheduled time. Extra tablets of CALQUENCE should not be taken to make up for a missed dose.
All patients were treated with topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California) on twice daily dose, in addition to the topical preservative free artificial tears Q.I. D.
The invention relates to an eye drop for preventing and treating angiogenesis diseases in the eye, particularly a spirulina polysaccharide eye drop, and a preparation method and an application thereof. The spirulina polysaccharide eye drop is prepared from spirulina polysaccharides extracted from spirulina powder. The eye drop comprises spirulina polysaccharides and artificial tears, wherein the concentration of spirulina polysaccharides is 100-500 mug/mL. The artificial tears can be replaced by Compound Sodium Chloride Eye drops. The invention prepares spirulina polysaccharides into an eye drop for treating and preventing angiogenesis diseases in the eye for the first time, and the preventing and treating effect is remarkably. The eye drop has the advantages of simple preparation method, convenient implementation, good therapeutic effect, and good application and development prospect.
Electrical Inhibition (EI) uterine pacemaker is activated only when there is a preterm uterine contraction. The EI uterine pacemaker delivers a 1-15mA (20mA maximum) constant direct current for only 2 seconds only while there is a preterm uterine contraction.
FIELD: antibiotics, pharmacy. SUBSTANCE: preparative form with sustained release of macrolide compound contains composition as solid dispersion. Macrolide compound in indicated solid dispersion presents in amorphous state on solid base. Preferably, macrolide compound represents tacrolimus or 33-epichloro-33-deoxyascomycin. Solid base is represented by water-soluble polymer, wax, water-insoluble polymer or their combination. In method for test carrying out for evaluation of pattern of dissolving the preparative form with indicated macrolide compound the test solution with concentration 0.001-0.1% of cellulose polymer is used at pH brought about to value 7, not above. After oral intake the novel preparative form releases macrolide compound by sustained pattern and pharmaceutical activity is maintained for a long time. Invention provides reduced frequency of pharmacologically active macrolide compound to 1 time per a day. The novel preparative form has no risk of adverse effects in case of random excessive concentration of macrolide compound. EFFECT: improved and valuable properties of preparations. 20 cl, 1 tbl, 34 ex
A system and method for organizing medical images as a single page representation are disclosed. The system comprises a computer-based platform hosting a patient management software application. The computer-based platform is used for displaying at least two digital medical images in at least one application window of the patient management software application. Each of the digital medical images is identified as being of a particular type of medical image. The computer-based platform is further used for displaying at least two page representation templates in at least one other application window of the patient management software application. Each of the page representation templates includes pre-defined, blank image holder areas which are each defined as corresponding to a particular type of medical image. The computer-based platform is also used for selecting one of the page representation templates based on at least one of the type and number of the displayed medical images. The computer-based platform is further used for importing the digital medical images into the selected page representation template. Each of the medical images is associated with one of the pre-defined image holder areas based on at least the medical image type. The computer-based platform is also used for displaying the selected page representation template having the imported medical images in an application window of the patient management software application. Each of the imported medical images is automatically sized and displayed in an associated image holder area of the selected template.
Patients receive enasidenib PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo a HCT 7-14 days after treatment. Within 30-100 days following the transplant, patients receive enasidenib QD. Treatment repeats every 28 days for 24 cycles in the absence of disease progression or unacceptable toxicity.
PURPOSE: Pre-eclampsia (PE) is a pregnancy-related complication. Eucommia is effective in the treatment of hypertensive disorders in pregnancy, but the specific effects and possible mechanisms of Eucommia granules (EG) in PE remain unknown. The aim of this study was to investigate the effects and possible mechanisms of EG in PE rats.
METHODS: Pregnant Sprague Dawley rats were divided into five groups (n = 6): the control group, the model group, the low-dose group, the medium-dose group, and the high-dose group of EG. The PE model was established by subcutaneous injection of levonitroarginine methyl ester. Saline was given to the blank and model groups, and the Eucommia granules were given by gavage to the remaining groups. Blood pressure and urinary protein were detected. The body length and weight of the pups and the weight of the placenta were recorded. Superoxide dismutase (SOD) activity and levels of malondialdehyde (MDA), placental growth factor (PIGF), and soluble vascular endothelial growth factor receptor-1 (sFIt-1) were measured in the placenta. Pathological changes were observed by hematoxylin-eosin staining. Wnt/β-catenin pathway-related protein expression was detected using Western blot.
RESULTS: Compared with the model group, the PE rats treated with EG had lower blood pressure and urinary protein. The length and weight of the pups and placental weight were increased. Inflammation and necrosis in the placental tissue was improved. SOD level increased, MDA content and sFIt-1/PIGF ratio decreased, and Wnt/β-catenin pathway-related protein expression level increased. Moreover, the results of EG on PE rats increased with higher doses of EG.
CONCLUSIONS: EG may activate the Wnt/β-catenin pathway and inhibit oxidative stress, inflammation, and vascular endothelial injury in PE rats, thereby improving the perinatal prognosis of preeclamptic rats. EG may inhibit oxidative stress, inflammation, and vascular endothelial injury through activation of the Wnt/β-catenin pathway in preeclampsia rats, thereby improving perinatal outcomes in PE rats.
According to a technical scheme on the first aspect, the invention provides a drug for treatment of polycystic ovary syndrome (PCOS) and abnormal glucose metabolism coexisting diseases. The drug is characterized by including the following four fatty acid components by mass: 17-22% of palmitic acid, 11-23% of hexadecenoic acid, 22-28% of 9-octadecenoic acid, 13-35% of 9, 12, 15-octatecatrienoic acid, and the balance pharmaceutically acceptable additives or excipients. The components are mixed according to compatibility to be prepared into soft capsules and other oral preparations, so that the insulin receptor substrate (IRS) protein level can be effectively reduced so as to inhibit the glucose way, the insulin receptor active time can be increased and the insulin level can be enhanced, and the insulin sensitivity is increased so as to facilitate the reduction of insulin resistance degree. Thus, the drug can have the functions of improving and recuperating ovary ovulatory dysfunction, i.e. PCOS and abnormal glucose metabolism diseases. Compared with other drugs, the drug has simple components, and belongs to highly effective, safety, and simplified drugs.
Tobacco is a male infertility risk factor. Many studies comparing smokers to non-smokers have shown effects on spermatogenesis and the quality of the male gamete. In vitro fertilization success rates are decreased in smokers and in natural procreation the time required to conceive (excellent fertility indicator) seems to be lengthened in the smoker. Tobacco is a well-known mutagen. It will induce damage to the male gametes DNA. Tobacco increases the oxydation of DNA. Exposure to tobacco increases the percentage of spermatozoa with broken DNA or defective chromatin and induces gametes aneuploidy as has been reported in several studies. The set of effects of tobacco on the male gametes questions the consequences for the conceptus (from embryo to adult). The prospective study that the investigators propose to carry out would make it possible to know the time required for the repair of the sperm abnormalities and in particular the DNA of the gametes generated by the smoking. Indeed, a cycle of spermatogenesis extending over 74 days, it would be important to know if it is necessary to wait a complete cycle or even more before proposing a management. It would therefore be possible to find the most favorable period for reducing tobacco-related risks and for effective management.

A blood test will be performed at T0 (before weaning) and during follow-up at 3, 6 and 12 months for the determination of the Inhibin hormones and testosterone. Sperm analysis at the different follow-up times will be carried out at CECOS using a standardized methodology (WHO). Two tests of analysis will be used in this study on each sample: the TUNEL test and the SCSA. A measurement of DNA oxidation will also be performed, as well as a study of spermatic aneuploidy (in situ hybridization technique of fluorescent centromeric chromosomal probes).
Participants were to receive orally 0.50 mg of MK-3614 BID every 12 hours on Day 1 followed by 3 doses (0.50/0.50/0.25 mg) of MK-3614 each 8 hours apart on Day 2; three doses of 0.50 mg of MK-3614 8 hours apart on Days 3,4; and 0.75 mg of MK-3614 BID every 12 hours on Days 5-14. No participants were enrolled in this group.
Enfortumab vedotin will be administered at 1.25 mg/kg on day 1 and day 8 of each 21-day cycle, for up to 6 cycles. Patients can proceed to surgery prior to completion of cycle 6 at the discretion of the investigator and urologist if toxicities prevent completion of 6 cycles of treatment. Enfortumab vedotin will be capped at a maximum dose of 125 mg for each infusion (for patients who weigh \> 100 kg). Pembrolizumab will be administered on day 1 of each cycle, every 21 days, for 6 cycles. After completion of 3 cycles patients with have imaging assessment, and patients with progression of disease as measured by distant metastases will be removed from the study. At completion of cycle 6, patients will have repeat imaging assessment and proceed to cystectomy within 4-8 weeks. Following cystectomy, patients will resume pembrolizumab monotherapy on day 1 of each 21-day cycle for an additional 11 doses (Cycles 7-17), to complete 1 year of pembrolizumab therapy.
Abnormal Wnt5a expression is associated with dysregulated inflammation and organ dysfunction. However, the effect of Wnt5a activation on the duration of organ dysfunction remains unclear. This prospective study investigated the association between Wnt5a levels and persistent acute kidney injury (AKI) in patients with urosepsis. Serum creatinine and Wnt5a levels were measured on days 1 and 5 and at discharge in 87 patients diagnosed with urosepsis. Patients with urosepsis were classified into an improving acute kidney injury (AKI) group and a persistent or worsening AKI group according to the AKI stage on days 1 and 5. AKI recovery was defined as a discharge-to-baseline serum creatinine ratio of <1.5. Twenty-eight patients with urosepsis (32.2%) had persistent or worsening AKI, and their Wnt5a levels were higher on days 1 and 5 and at discharge than those with improving AKI. The association between Wnt5a levels and persistent or worsening AKI was maintained after adjusting for age, sex, baseline serum creatinine levels, and disease severity. Moreover, elevated Wnt5a levels were associated with an increased risk of major adverse kidney events. High Wnt5a levels at discharge were associated with unrecovered AKI and participants with AKI recovery had a steeper Wnt5a slope over time than those without recovery, irrespective of age, sex, baseline serum creatinine level, or disease severity. Assessment of Wnt5a expression was helpful in predicting AKI persistence and adverse outcomes in patients with urosepsis. Therefore, Wnt5a may serve as a valuable bio-marker for identifying the risk of persistence of AKI.